The International, Prospective COSMOS (CytOSorb® TreatMent Of Critically Ill PatientS) Registry: Interim Results in Patients with Septic Shock - PubMed
6 hours ago
- #Clinical Registry
- #Hemoadsorption
- #Septic Shock
- The COSMOS Registry collects real-world data on CytoSorb hemoadsorption in critically ill patients, focusing on septic shock.
- Analysis of 140 patients showed significant reductions in IL-6 levels and norepinephrine requirements after CytoSorb therapy.
- Treatment also improved fluid balance and oxygenation but reduced platelet counts, while overall SOFA scores did not change significantly.
- No serious device-related adverse effects were reported, and ICU mortality was 32.4%.
- CytoSorb therapy was associated with hemodynamic stabilization and improved fluid balance, requiring further research to optimize use.